Eradication of @entity19 @entity320 by combined treatment with recombinant @entity1 @entity1199 and recombinant XXXX interferon-gamma.

@entity1 @entity137 @entity3692 @entity19 @entity5 @entity60 @entity5041 @entity1199 @entity320
Successful immunotherapy of early s.c. or i.p. (B16) @entity320 in syngeneic C57BL/6 (B6) @entity19 was achieved with s.c. peri-lesional injections (for s.c. @entity5 ) or i.p. injections (for i.p. @entity5 ) of recombinant @entity1 @entity1199 ( @entity5041 ) and recombinant @entity19 interferon-gamma ( @entity3692 ). Over a 28-day period, @entity5041 and @entity3692 were injected 14 times. Results with this combination were additive with s.c. @entity5 and synergistic with i.p. @entity5 . Treatment with 6,250 U-25,000 U of @entity5041 and 2 micrograms of @entity3692 began 1-3 days after s.c. inoculation of @entity320 . On day 50, 87% (72/83) of @entity19 thus treated were completely free of @entity5 . None of the 78 control @entity19 ( @entity5 + buffer) survived. Of @entity19 receiving either @entity5041 or @entity3692 alone, 59% (47/79) and 53% (44/83), respectively, were @entity5 -free. I.p. @entity5 were also eradicated by i.p. injections of @entity5041 (50,000 U) with @entity3692 (5, 10, and 15 micrograms) as judged by absence of @entity5 in 81% (21/26) of @entity19 autopsied between days 45 and 65. No control @entity19 survived, and only 17% (2/12) and 20% (6/30) given either @entity5041 or @entity3692 separately (i.p.) were @entity5 -free. Doses of @entity3692 from 1-4 micrograms were more beneficial in eliminating 1-day s.c. @entity320 than were higher doses, and local s.c. treatment was far superior to distant or systemic treatment. Non-adherent peritoneal or splenic cells from @entity19 bearing 6-day-old i.p. @entity320 and treated with one or both lymphokines on days 3 and 4 were used in @entity137 assays in vitro. Significant @entity137 against cultured @entity320 cells was displayed by cells harvested from lymphokine-treated @entity19 , but there was no evidence of the synergism observed with combination treatment of i.p. @entity5 in vivo. @entity3692 inhibited proliferation of @entity320 cells in vitro, whereas @entity5041 stimulated proliferation at 1,000 U/ml. Plating efficiency was increased by at least 30% by culture with 100 U or 1,000 U of @entity5041 /ml and both concentrations neutralized the inhibitory effect of 0.05 ng/ml of @entity60 , but not of 0.5 or 5.0 ng/ml.
